PCSK9: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 7: | Line 7: | ||
== Structural highlights == | == Structural highlights == | ||
*<scene name='55/553967/Cv/ | *<scene name='55/553967/Cv/7'>PCSK9 catalytic domain interactions with LDL receptor EGF-A domain</scene>. Water molecules are shown as red spheres. | ||
*<scene name='55/553967/Cv/ | *<scene name='55/553967/Cv/8'>PCSK9 Ca coordination site</scene>. | ||
*<scene name='55/553967/Cv/ | *<scene name='55/553967/Cv/9'>LDL receptor Ca coordination site</scene>. | ||
</StructureSection> | </StructureSection> | ||
==3D structures of PCSK9== | ==3D structures of PCSK9== | ||
| Line 15: | Line 15: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
[[2p4e]], [[2pmw]], [[2qtw]] – hPCSK9 – human <br /> | [[2p4e]], [[2pmw]], [[2qtw]], [[8wfr]] – hPCSK9 – human <br /> | ||
[[3bps]], [[2w2m]], [[3gcx]] – hPCSK9 + LDLR EGF-A <br /> | [[3bps]], [[2w2m]], [[3gcx]] – hPCSK9 + LDLR EGF-A <br /> | ||
[[2w2n]], [[3gcw]] – hPCSK9 + LDLR EGF-A (mutant)<br /> | [[2w2n]], [[3gcw]] – hPCSK9 + LDLR EGF-A (mutant)<br /> | ||
[[2w2o]], [[2w2p]], [[2w2q]] – hPCSK9 (mutant) + LDLR EGF-A <br /> | [[2w2o]], [[2w2p]], [[2w2q]], [[7kev]], [[7kfa]] – hPCSK9 (mutant) + LDLR EGF-A <br /> | ||
[[2xtj]], [[3sqo]], [[4k8r]], [[5vl7]] – hPCSK9 + antibody <br /> | |||
[[3h42]] – hPCSK9 (mutant) + antibody <br /> | [[3h42]] – hPCSK9 (mutant) + antibody <br /> | ||
[[ | [[6u26]], [[6u2n]], [[6u2p]] – hPCSK9 + inhibitor<br /> | ||
[[6u2f]], [[6u36]], [[6u38]], [[6u3i]], [[6u3x]] – hPCSK9 + antibody + inhibitor<br /> | |||
[[4nmx]], [[5vla]], [[5vlh]], [[5vkl]], [[5vll]], [[6xib]], [[6xic]], [[6xid]], [[6xie]], [[6xif]], [[7s5h]], [[8fpk]], [[8fpq]], [[8fvl]], [[8fvm]], [[8fvn]], [[8fvo]], [[8fvp]], [[8fvq]], [[8vdv]] – hPCSK9 + peptide inhibitor<br /> | |||
[[6e4y]], [[6e4z]], [[6mv5]] – hPCSK9 N terminal + antibody <br /> | |||
[[7s5g]] – hPCSK9 + peptide + inhibitor<br /> | |||
[[6u2f]], [[6u3i]] – hPCSK9 + antibody + peptide inhibitor<br /> | |||
[[3m0c]] – hPCSK9 (mutant) + LDLR <br /> | [[3m0c]] – hPCSK9 (mutant) + LDLR <br /> | ||
[[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br /> | [[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br /> | ||
[[4ov6]] – hPCSK9 + adnectin <br /> | [[4ov6]] – hPCSK9 + adnectin <br /> | ||
[[7anq]] – hPCSK9 C terminal + VHH minibody <br /> | |||
[[6olz]], [[6om0]], [[6om7]] – hPCSK9 in ribosome – Cryo EM <br /> | |||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Latest revision as of 08:50, 20 April 2026
| ||||||||||||
3D structures of PCSK9
Updated on 20-April-2026
Pro-protein convertase subtilisin/kexin type 9 (PCSK9), 2pmw, 2qtw, 8wfr – hPCSK9 – human
3bps, 2w2m, 3gcx – hPCSK9 + LDLR EGF-A
2w2n, 3gcw – hPCSK9 + LDLR EGF-A (mutant)
2w2o, 2w2p, 2w2q, 7kev, 7kfa – hPCSK9 (mutant) + LDLR EGF-A
2xtj, 3sqo, 4k8r, 5vl7 – hPCSK9 + antibody
3h42 – hPCSK9 (mutant) + antibody
6u26, 6u2n, 6u2p – hPCSK9 + inhibitor
6u2f, 6u36, 6u38, 6u3i, 6u3x – hPCSK9 + antibody + inhibitor
4nmx, 5vla, 5vlh, 5vkl, 5vll, 6xib, 6xic, 6xid, 6xie, 6xif, 7s5h, 8fpk, 8fpq, 8fvl, 8fvm, 8fvn, 8fvo, 8fvp, 8fvq, 8vdv – hPCSK9 + peptide inhibitor
6e4y, 6e4z, 6mv5 – hPCSK9 N terminal + antibody
7s5g – hPCSK9 + peptide + inhibitor
6u2f, 6u3i – hPCSK9 + antibody + peptide inhibitor
3m0c – hPCSK9 (mutant) + LDLR
3p5b, 3p5c – hPCSK9 + LDLR variant
4ov6 – hPCSK9 + adnectin
7anq – hPCSK9 C terminal + VHH minibody
6olz, 6om0, 6om7 – hPCSK9 in ribosome – Cryo EM
